Stock KYMR KYMERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
33.62 USD -3.00% Intraday chart for Kymera Therapeutics, Inc. -5.85% +32.05%
Apr. 22 Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target MT
Apr. 08 Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
GL
Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target
MT
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
GL
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
AQ
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting
CI
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board
CI
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing
MT
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
AQ
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
GL
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting
CI
Truist Ups Price Target on Kymera Therapeutics to $54 From $41, Keeps Buy Rating
MT
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
GL
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
AQ
Piper Sandler Raises Price Target on Kymera Therapeutics to $56 From $39, Maintains Overweight Rating
MT
B. Riley Adjusts Kymera Therapeutics' Price Target to $31 From $16, Keeps Neutral Rating
MT
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises
MT
Transcript : Kymera Therapeutics, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KYMR Stock
  4. News Kymera Therapeutics, Inc.